Mineralocorticoid receptor antagonists for the prevention of atrial fibrillation in patients with and without heart failure: one more beneficial effect?-Reference-Cited by-同舟云学术

Mineralocorticoid receptor antagonists for the prevention of atrial fibrillation in patients with and without heart failure: one more beneficial effect?

Published:2024-02-06 Issue: Volume: Page:
ISSN:0195-668X
Container-title:European Heart Journal
language:en
Short-container-title:

Author:

Zurkan Daniela¹²³^ORCID,Pitt Bertram⁴^ORCID,Edelmann Frank¹²³^ORCID

Affiliation:

1. Department of Cardiology, Deutsches Herzzentrum der Charité, Angiology and Intensive Care Medicine , Augustenburger Platz 1, D-13353 Berlin , Germany

2. Charité—Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin , Charitéplatz 1, D-10117 Berlin , Germany

3. DZHK (German Centre for Cardiovascular Research), Partner site Berlin , Berlin , Germany

4. University of Michigan School of Medicine , Ann Arbor, MI , USA

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

Link

https://academic.oup.com/eurheartj/advance-article-pdf/doi/10.1093/eurheartj/ehae040/56590323/ehae040.pdf

Reference15 articles.

1. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators;Pitt;N Engl J Med,1999

2. Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation;Tsai;J Am Coll Cardiol,2010

3. The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation;Lavall;J Biol Chem,2014

4. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in heart failure) study;Swedberg;J Am Coll Cardiol,2012

5. Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis;Liu;Europace,2016